-
Targeted Genetic Nanoparticle Company Gains $25M in Seed Funds
A developer of nanoscale lipid particles for delivering genomic therapies to specific cells and tissue, spun-off from academic labs, is raising $25 million in seed funds.
-
Vaccine Patch Shown Safe, Induces Immune Response
Initial results from a clinical trial show a patch device delivering a Covid-19 vaccine is well tolerated by recipients and triggers a measurable immune response.
-
Photography Project Today
We will resume our regular posting tomorrow.
-
Infographic – VR, AR Yet to Reach Critical Mass
While applications of VR and AR technologies can seem compelling, the numbers of people actually using these systems remain relatively small.
-
Primate Genome A.I. Model IDs Human Disease Variants
A genomic systems company created an artificial intelligence algorithm from primate genomic data that identifies possible disease-causing mutations in humans.
-
Clinical Trial Begins for Peanut Allergy Treatment
A clinical trial is underway testing an experimental therapy for peanut allergy that its developer says trains the immune system without using peanut proteins.
-
Crispr Therapy Shown to Reduce Harmful Gut Microbes
A clinical trial shows an oral therapy with engineered viruses delivers precise gene-edited payloads to reduce E. coli communities in the gut with no serious adverse effects.
-
Precision T-Cell Solid Tumor Therapy Trial Underway
A clinical trial has begun testing a treatment for solid tumor cancers using engineered T-cells with proteins to attack specific tumor cells, but also avoid healthy cells.
-
Memorial Day, 2023
We’ll resume our editorial posting tomorrow.
-
Infographic – More US Support for Childhood Vaccines Than Covid-19
A recent poll shows U.S. adults continue to favor vaccinations against the childhood diseases mumps, measles, and rubella, but show less support for Covid-19 vaccines.